Literature DB >> 2708740

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma.

J Bousquet1, A Hejjaoui, H Dhivert, A M Clauzel, F B Michel.   

Abstract

Specific immunotherapy can induce severe systemic reactions (SRs), especially in patients with asthma. It also appears that potent standardized extracts may be more often involved in the generation of SRs than other extracts. Since these SRs may be potentially life threatening, it is desirable to predict their onset. A prospective study was carried out in 125 mite-allergic subjects with asthma ranging in age from 4 to 57 years to assess the incidence of SRs during a rush immunotherapy (RIT) protocol and maintenance injections and to attempt to predict the onset of the SRs. All patients received the same standardized extract of Dermatophagoides pteronyssinus with the same RIT and the same maintenance dose (3000 BU in subjects older than 10 years and 1500 BU in children younger than 10 years). Patients were carefully monitored during the RIT protocol, and possible SRs were followed for up to 2 hours after injections. Patients then received maintenance injections for a mean duration of 18.2 +/- 5.6 months. During maintenance injections, patients were under supervision of a physician for 30 minutes. Within 2 weeks before the RIT, all patients older than 6 years had a pulmonary function test, skin prick test end point with the standardized D. pteronyssinus extract, and RAST. The severity of asthma was examined with the score of Aas. Forty-seven patients had an SR during the RIT protocol: four mild generalized urticaria, 35 asthma exacerbations, and eight anaphylactic shocks. None of the patients had to be admitted to an intensive care unit. Most SRs started within 15 minutes, and none of the SRs started 45 minutes or later after the last injection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2708740     DOI: 10.1016/0091-6749(89)90017-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

Review 1.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 2.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 3.  Clinical immunology review series: an approach to desensitization.

Authors:  M T Krishna; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

Review 4.  Fatalities following allergen immunotherapy.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 5.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 6.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

7.  Safety of sublingual immunotherapy in children with asthma.

Authors:  Giovanni B Pajno; Diego G Peroni; Daniela Vita; Angelo Pietrobelli; Silvano Parmiani; Attilio L Boner
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement.

Authors:  Yousef A Taher; Paul A J Henricks; Antoon J M van Oosterhout
Journal:  Libyan J Med       Date:  2010-06-21       Impact factor: 1.657

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.